Efficacy of brolucizumab on AMD in patients exhibiting aflibercept resistance

Efficacy of brolucizumab on AMD in patients exhibiting aflibercept resistance - AMD treated by anti-VEGF drugs

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044180

Enrollment

Registered

2021-05-12

Start date

2020-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AMD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with nAMD switched from aflibercept to brolucizumab between June 2020 to December 2020 at Nagoya University Hospital.

Exclusion criteria

Exclusion criteria: nothing special

Design outcomes

Primary

Measure	Time frame
Sex, age, visual acuity, visual field, refraction, corneal curvature radius, corneal thickness, ocular axial length, fundus observation,Optical coherence tomography, optical coherence tomography angiography, fundus photograph, fluorescence fundus angiography, slit lamp microscopy, duration of disease, current medical history, past history, family history, medication used, frequency of dosing	—

Countries

Japan

Contacts

Public Contactjun Takeuchi

Nagoya University Hospital Department of Ophthalmology

takeuchi.jun@med.nagoya-u.ac.jp052-744-2275

Outcome results